• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • Measures for the Administration of Drug Registration in China

Measures for the Administration of Drug Registration in China

Measures for the administration of drug registration
Monday, 25 April 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Measures for the Administration of Drug Registration in China

Measures for the Administration of Drug Registration was issued by China’s State Administration for Market Regulation (SAMR) on March 1, 2020, and came into effect on July 1, 2020. In order to meet the requirements of the Drug Administration Law and Vaccine Administration Law, the measures aim to reform the drug review and approval system. This post is a reminder to drug manufacturers about key registration requirements for their China registration projects.

Measures for the Administration of Drug Registration in China – Highlights

A summary of the key points of the Measures for Administration of drug Registration has been prepared by Cisema’s experts below.

  • Drug registration means that an applicant for drug registration submits applications for drug clinical trials, drug marketing authorization, drug renewal, and supplementary applications in accordance with legal procedures and relevant requirements. Based on laws and regulations and existing scientific knowledge, the drug supervision and administration department will review the safety, effectiveness and quality controllability of the drug, and decide whether to approve the application.
  • Drugs are divided into TCM (Traditional Chinese Medicine), chemical drug, and biological product for classified management. NMPA has successively issued registration classification and application dossier requirements for biological products, chemical drugs, and traditional Chinese medicines. For details, please refer to No. 43-2020, No. 44-2020, and No.68-2020.
  • Before applying for drug marketing registration, applicants shall complete relevant research work such as pharmacy, pharmacology and toxicology, and drug clinical trials. Drug non-clinical safety evaluation studies should be conducted in a facility accredited by Good Laboratory Practice(GLP) and in compliance with the requirements of the GLP. Drug clinical trials shall be approved, and bioequivalence trials shall be filed. Drug clinical trials should be conducted in drug clinical trial institutions that comply with relevant regulations and comply with the requirements of GCP.
  • NMPA establishes a drug registration system for accelerated marketing to support clinical value-oriented drug innovation. For qualified drug registration applications, applicants can apply for breakthrough therapy drugs, conditional approval, priority review approval and special approval procedures. For details, please refer to No. 82-2020.
  • NMPA establishes an associated review and approval system for chemical raw materials, excipients, and packaging materials and containers in direct contact with drugs. During the technical review of the drug, the chemical raw materials, related excipients, packaging materials and containers that directly contact the drug are reviewed together.
  • Implement classified registration and conversion management for prescription drugs and OTC. The Center for Drug Evaluation (CDE) is responsible for formulating technical guidelines and procedures related to the marketing registration of OTC drugs. The CDE is responsible for formulating technical requirements and procedures related to post-market conversion of prescription and non-prescription drugs. It has not been officially released yet, and is still in the draft stage.
  • Applicants may communicate with professional and technical institutions such as the CDE on major issues before applying for drug clinical trials, during the process of drug clinical trials, and before applying for drug marketing authorization.  For details, please refer to CDE’s No. 48 of 2020.

By Yu and Jacky. If you would like to learn more about Measures for the Administration of Drug Registration or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods contact Cisema.

Tagged under: drug, drug registration, pharmaceutical

What you can read next

Hot Topic: Beauty Devices Regulated As Medical Devices – A Trend to Continue
Cisema Participates in VDDI Quarterly Meeting
Drug Release Studies Proposed for Combination Products

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.